Skip to content

Identify Characteristics of Similar Chinese Patent Medicine for Stroke

Identify Characteristics of Similar Chinese Patent Medicine for Stroke: a Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17010397
Enrollment
Unknown
Registered
2017-01-11
Start date
2018-07-01
Completion date
Unknown
Last updated
2017-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

STROKE

Interventions

Sponsors

Tianjin University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 30 to 65 years old; 2. The first onset of stroke; 3. Diagnosis of unilateral, non-recurring, subacute stroke of ischemic and lacunar type, as defined by the International Classification of Diseases (ICD-10) through computed omography or magnetic resonance imaging conducted by neurologists; 4. Meet the TCM pattern diagnosis of stroke in meridian syndrome; 5. Patients should have a score between 6 and 20 according to National Institutes of Health Stroke Scale (NIHSS); 6. Four weeks to eight weeks after onset of stroke; 7. Provision of signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with a known history of allergy or suspected allergy to the medicines used in the study; 2. Patients who suffered from serious heart, liver or kidney-related diseases, blood coagulation dysfunction or severe mental disorders; 3. Patients with other complications; 4. Uncontrolled NYHA class III hypertension (systolic blood pressure =180 mmHg and/or diastolic blood pressure =110 mmHg); 5. Fasting blood glucose 16.8 mmol/l or with severe complications due to diabetes (e.g., diabetic gangrene, or peripheral neuropathy); 6. Liver function impairment with the value of ALT or AST over 1.5-fold the upper limit of normal range; 7. Renal dysfunction with the value of serum creatinine over 1.5-fold the upper limit of normal range; 8. Patients with active peptic ulcers or other hemorrhagic diseases; 9. Patients who participate in other clinical trials, either currently or within the past 90 days.

Design outcomes

Primary

MeasureTime frame
NIHSS;WHOQOL-BREF;

Countries

China

Contacts

Public ContactHuiling Chen

Tianjin University of Traditional Chinese Medicine

373380535@qq.com+86 18522601370

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 25, 2026